Oncoheroes 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«123456789101112»
  • ||||||||||  volasertib (BI 6727) / Oncoheroes
    Preclinical, Journal:  Volasertib preclinical activity in high-risk hepatoblastoma. (Pubmed Central) -  Nov 22, 2019   
    As a potential therapeutic strategy, we tested the combination of volasertib and the relapse-related hepatoblastoma chemotherapeutic irinotecan. We found both in vitro and in vivo efficacy of this combination, which may merit further preclinical investigation and exploration for a clinical trial concept.
  • ||||||||||  azacitidine / Generic mfg.
    Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_6410;    
    The broad receptor tyrosine kinase inhibitor Dovitinib and the DNA methyltransferase inhibitor Azacytidine elicited strong responses in all iPSC cell lines regardless of their KRAS, NRAS or NF1 state...Experimental studies analyzing the underlying mechanism of its differential effect on KRAS wildtype compared to KRAS-G12D cells are currently carried out and will be presented. Our results suggest, that iPSCs with RAS pathway activation due to stable expression of oncogenic KRAS or NRAS or downregulation of NF1 expression are valuable tools for preclinical testing and may identify promising novel lead compounds for JMML treatment.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Imbruvica (ibrutinib) / AbbVie, J&J
    Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_5797;    
    Our data demonstrated that pan-PI3K inhibitor copanlisib and PLK1 inhibitor volasertib are potent agents in targeting MCL cells in vitro and in vivo, and they have great potential to overcome ibrutinib and venetoclax resistance in MCL. When combined, copanlisib and volasertib have even greater potential to overcome ibrutinib and venetoclax resistance in MCL.
  • ||||||||||  Review, Journal:  The 8p11 myeloproliferative syndrome: a review of recent literature (Pubmed Central) -  Oct 28, 2019   
    Therefore, at present, allo-hematopoietic stem cell transplantation is the only curative methods for EMS. Very recently, a phase-2 study with pemigatinib, an inhibitor for FGFR1, showed clinical benefits for EMS patients, including major cytogenetic response, suggesting a new therapeutic option for EMS.
  • ||||||||||  Biomarker, Clinical, Review, Journal, BRCA Biomarker, PARP Biomarker:  Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. (Pubmed Central) -  Oct 27, 2019   
    Other newer agents such as talazoparib, veliparib, 2X-121, and CEP-9722 are in earlier stages of development. As more FDA-approved indications for PARP inhibitor therapy in ovarian cancer become available, we anticipate the decision of which PARP inhibitor to use will become increasingly complex.
  • ||||||||||  paclitaxel / Generic Mfg.
    Mitosis leakage and Mcl1 inhibition as a therapeutic approach in solid tumors (M8) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1536;    
    In NSCLC highly efficient mitotic arrest with subsequent apoptosis in mitosis was reached by combining an antimitotic agent and a direct APC/C-inhibitor, blocking cyclin B-proteolysis and mitotic exit using low doses achievable in vivo. A similar effect was reached with the combination with an unspecific PI.
  • ||||||||||  paclitaxel / Generic mfg.
    Tumor suppressor PLK2 may serve as a biomarker in triple negative breast cancer for combinational therapy of PLK1 inhibitors with the standard-of-care chemotherapy (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1267;    
    Furthermore, we demonstrated that PLK2 interacted with PLK1 using a bimolecular fluorescence complementation assay and by co-immunoprecipitation, and using a proximity ligation assay this interaction was shown to occur in prometaphase.Due to the lack of targeted therapy, chemotherapy, such as carboplatin usually in combination with Taxol, is still one of the only systematic treatments for TNBC...Combinational treatment with the PLK1 inhibitor Volasertib and carboplatin showed a strong synergistic effect on tumor growth and led to regression of the Plk2/p53 null claudin-low tumors, but not control Plk2+/p53 null claudin-low tumors...We hope that these preclinical experiments will provide a rationale for the application PLK1 inhibitors in combination with chemotherapy in a subset of TNBC patients with deletion of PLK2. [Supported by Susan G. Komen Foundation grant SAC110031]
  • ||||||||||  temozolomide / Generic Mfg., volasertib (BI 6727) / Boehringer Ingelheim
    Inhibition of PLK1 abrogates side population and increases radiosensitivity of human glioblastoma (Board 68: Level 2 - Hall D) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_103;    
    Experimental Design: We tested PLK1 inhibitor volasertib in combination with temozolomide (TMZ) and ionizing radiation on GBM cells to evaluate its effect on stemness, DNA repair and GBM promoting signaling. Volasertib and its combination with TMZ and ionizing radiation provide unique opportunity for multi-targeted approach to overcome resistance of GBM cells which is observed during current treatment regimen and could be further tested in clinical trials.
  • ||||||||||  BI2536 / Boehringer Ingelheim, volasertib (BI 6727) / Boehringer Ingelheim
    Journal:  BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. (Pubmed Central) -  Sep 18, 2019   
    We also found that BI-2536 synergistically activates the latent provirus in combination with SAHA, a histone deacetylase inhibitor, or the non-tumour-promoting phorbol ester prostratin. Our findings strongly suggest that BI-2536 and BI-6727 are potent LRAs for the "shock and kill" HIV-1 eradication strategy.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, volasertib (BI 6727) / Oncoheroes
    Journal, IO biomarker:  PLK1: a promising and previously unexplored target in double-hit lymphoma. (Pubmed Central) -  Sep 8, 2019   
    PLK1 inhibition with volasertib, alone and in combination with the BCL-2 inhibitor venetoclax, was efficacious in multiple DHL models, including mice harboring DHL patient-derived xenografts. Together, these data support PLK1 as a promising prognostic marker and therapeutic target for DHL.
  • ||||||||||  cisplatin / generics
    Preclinical, Journal:  Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro. (Pubmed Central) -  Aug 29, 2019   
    The combination of multi-kinase inhibitors and conventional chemotherapy in HNSCC may strengthen the use of current therapeutic strategies; nintedanib appears to be the most suitable TKI for combination therapy. Further efforts are required to classify TKI efficacy with regard to cisplatin resistance.
  • ||||||||||  dovitinib (TKI258) / Novartis, Oncoheroes
    Trial completion, Metastases:  TKI258 for Metastatic Inflammatory Breast Cancer Patients (clinicaltrials.gov) -  Jul 30, 2019   
    P2,  N=22, Completed, 
    Taken together, our results suggest that PLK1 might be a diagnostic or therapeutic marker for OSCC. Active, not recruiting --> Completed
  • ||||||||||  TAK-733 / Takeda, volasertib (BI 6727) / Boehringer Ingelheim
    Preclinical, Journal:  A cell based, high throughput assay for quantitative analysis of Hedgehog pathway activation using a Smoothened activation sensor. (Pubmed Central) -  Jul 4, 2019   
    Furthermore, monitoring Smo activation at the single cell level indicated that individual cells exhibit different threshold responses to Hh stimulation, which may be mechanistically relevant for the formation of graded Hh responses. Together, these results thus provide proof of principle that our assay may become a valuable tool for dissecting the cell biological basis of Hh pathway activation.
  • ||||||||||  volasertib (BI 6727) / Boehringer Ingelheim
    Journal:  Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine. (Pubmed Central) -  Jun 15, 2019   
    Even though the future impact of PLK1-tailored treatment still needs validation, much more pre-clinical and clinical research for this kinase is warranted. The pharmacokinetics of volasertib in patients with acute myeloid leukaemia alone or in combination with cytarabine is predictable and associated with low-to-mild patient variability with the exception of the high variability associated with the volume of distribution of the central compartment, having no effect on the area under the plasma concentration-time curve.
  • ||||||||||  BI 894999 / Boehringer Ingelheim, volasertib (BI 6727) / Boehringer Ingelheim
    Biomarker, Preclinical, Journal:  Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. (Pubmed Central) -  May 7, 2019   
    Co-administration of BI 894999 and volasertib dramatically reduces tumor burden accompanied by long-term survival of tumor-bearing mice and eradication of AML cells in mouse bone marrow. Together, these preclinical findings provide evidence for the strong synergistic effect of BI 894999 and volasertib, warranting future clinical studies in patients with AML to investigate this paradigm.
  • ||||||||||  volasertib (NBL-001) / Oncoheroes, Notable Labs
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) -  Aug 9, 2018   
    P1,  N=1, Terminated, 
    Trial completion date: Jan 2019 --> Aug 2019 N=70 --> 1 | Trial completion date: Nov 2016 --> Jul 2016 | Trial primary completion date: Nov 2016 --> Jun 2016
  • ||||||||||  Journal:  Signature program: a platform of basket trials. (Pubmed Central) -  May 17, 2018   
    The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.
  • ||||||||||  dovitinib (TKI258) / Allarity Therap, Oncoheroes
    Biomarker, Clinical, P2 data, Journal:  A Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. (Pubmed Central) -  Apr 24, 2018   
    Dovitinib produced few objective responses in patients with ACC but did suppress the TGR with a PFS that compares favorably to those reported with other targeted agents. Future studies of more potent and selective FGFR inhibitors in biomarker-selected patients will be required to determine if FGFR signaling is a valid therapeutic target in ACC.